For Boxed Warning, Prescribing Information, and Important Safety Information, see?https://lnkd.in/gFi3bXxE
关于我们
Please see Prescribing Information and Important Safety Information, including Boxed Warning, below. A leader in aesthetic neurotoxins for decades, BOTOX? Cosmetic is the only neurotoxin that’s FDA approved for simultaneous treatment in adults for 3 areas of the face: to temporarily improve the appearance of moderate to severe forehead line, lateral canthal lines, and glabellar lines.1-5 Follow our page to learn how BOTOX? Cosmetic can support you and your patients. REFERENCES: 1. BOTOX? Cosmetic Prescribing Information, July 2020. 2. Dysport? Prescribing Information, January 2023. 3. Xeomin? Prescribing Information, August 2021. 4. Jeuveau? Prescribing Information, January 2020. 5. Daaxify? Prescribing Information, September 2022.
- 网站
-
https://hcp.botoxcosmetic.com/
BOTOX? Cosmetic (onabotulinumtoxinA)的外部链接
- 所属行业
- 制药业
- 规模
- 超过 10,001 人
- 总部
- Irvine，CA
动态
-
For Boxed Warning and full Prescribing Information, see https://lnkd.in/gFi3bXxE - BOTOX? Cosmetic is a prescription medicine that is injected into muscles and used to temporarily improve the look of moderate to severe forehead lines, lateral canthal lines, glabellar lines, and platysma bands in adults.2 - BOTOX? Cosmetic is the first and only neurotoxin FDA approved to temporarily improve the appearance of moderate to severe platysma bands in adults.2-7 Contact Medical Information for more: visit abbviemedinfo.com – WARNING: DISTANT SPREAD OF TOXIN EFFECT – Postmarketing reports indicate that the effects of BOTOX? Cosmetic and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity, but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have an underlying condition that would predispose them to these symptoms. In unapproved uses and approved indications, cases of spread of effect have been reported at doses comparable to those used to treat cervical dystonia and spasticity and at lower doses. - Please see additional Important Safety Information in the video. - Intended for US healthcare professionals only.